Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 11

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 11
---
30 and 960 days, and overall survival ranged between 776 and 1147 days. These findings suggest a potential advantage in terms
of PFS and OS for the lower dose group, although they may be influenced by the slightly better baseline status of the patients in the
106 CFU dose group.

VXM01 phase I clinical trial — Immune response

The effect of VXM01 was explored by evaluating the VEGFR-2 specific
T cell response and frequency of immune cells in peripheral blood, and by staining of immune- and biomarkers in tumor tissue obtained
during resection.

Peripheral T-cell response:

All 9 tested patients showed a VEGFR2-specific T-cell and
IFN-γ immune response, with a clear increase observed after the initial vaccination and further increases after the first booster
dose. This indicates that VXM01 effectively stimulated an immune response against VEGFR2, a protein involved in tumor growth.

7

ELISpot assay was used to measure the number of these T cells that
produced interferon gamma (IFN-γ) when stimulated with different fragments of the VEGFR-2 protein.

    Mean difference count pool-all minus negative control
     
    106 CFU; mean ± SD (N)
     
    107 CFU; mean ± SD (N)
     
    Total; mean ± SD (N)
  
    Day 0
     
    4.5 ± 6.22 (3)
     
    18.1 ± 17.64 (5)
     
    13.0 ± 15.46 (8)
  
    Day 21
     
    14.5 ± 10.35 (3)
     
    10.4 ± 17.13 (4)
     
    12.2 ± 13.68 (7)
  
    Day 35
     
    8.4 ± 7.06 (3)
     
    13.4 ± 15.36 (5)
     
    11.6 ± 12.48 (8)
  
    Week 12 + 10 days
     
    -17.5 (2)